NASDAQ: ATHAAthira Pharma Inc Stock
$4.07+0.08 (+2.01%)
Updated Oct 24, 2025
ATHA Price
$4.07
Fair Value Price
$12.27
Market Cap
$16.05M
52 Week Low
$2.20
52 Week High
$8.26
P/E
-0.26x
P/B
0.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$59.85M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$71M
Beta
1.29
Next Earnings
Nov 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ATHA Overview
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company developing small molecules to restore neuronal health and stop neurodegeneration brought on by Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease.Known as M3 Biotechnology, Inc. until 2019/04, the company was incorporated in 2011 and is headquartered in Bothell, WA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATHA's potential to beat the market
- ATHA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATHA
RankedUnranked of 486
RankedUnranked of 486
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.28 | A | |
| $11.89 | A | |
| $7.20 | A |
Be the first to know about important ATHA news, forecast changes, insider trades & much more!
ATHA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATHA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATHA ($4.07) is undervalued by 66.83% relative to our estimate of its Fair Value price of $12.27 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ATHA ($4.07) is significantly undervalued by 66.83% relative to our estimate of its Fair Value price of $12.27 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ATHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ATHA due diligence checks available for Premium users.
Valuation
ATHA fair value
Fair Value of ATHA stock based on Discounted Cash Flow (DCF)
Price
$4.07
Fair Value
$12.27
Undervalued by
66.83%
ATHA ($4.07) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ATHA ($4.07) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ATHA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATHA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
-88.22x
Market
38.93x
ATHA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
4.92x
ATHA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ATHA's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.0M
Profit Margin
0%
ATHA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$35.5M
Liabilities
$3.6M
Debt to equity
0.11
ATHA's short-term assets ($32.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATHA's short-term assets ($32.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATHA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATHA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.0M
Investing
$441.0k
Financing
$24.0k
ATHA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATHA vs Biotech Stocks
Athira Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.